Lancet February 2026 Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

This study highlights a critical gap in global health policy, as liver diseases like MASLD and MASH are currently missing from the World Health Organization’s primary strategies for non-communicable diseases. By surveying hundreds of international experts, the research establishes a strong global consensus on fifteen essential interventions that should be prioritized for their high impact and feasibility. The findings emphasize that managing obesity and type 2 diabetes is the most effective long-term strategy, while routine fibrosis screening offers the most immediate public health benefit. Ultimately, the text serves as a strategic roadmap for policymakers, urging them to integrate liver health into broader health agendas to better combat the rising tide of chronic disease.